Volume 7, Issue 3 (7-2019)                   JoMMID 2019, 7(3): 52-60 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sharifi I, Aflatoonian M R, Babaei Z, Sharifi F, Keyhani A, Salarkia E, et al . Emerging Epidemics of Cutaneous Leishmaniasis in Iran: Operational Aspects, Management and Implemented Control Approaches. JoMMID. 2019; 7 (3) :52-60
URL: http://jommid.pasteur.ac.ir/article-1-196-en.html
Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran
Abstract:   (680 Views)
Cutaneous leishmaniasis (CL) in Iran could be considered as an emerging disease that is rapidly increasing and expanding its traditional geographical range to new foci. Sixteen registered emerging epidemics have occurred since 1998 in different provinces. Various risk factors, including agricultural development, earthquake, movement to endemic areas, construction of buildings near colonies of rodents, sleeping outside, cross-border movements, and poor sanitation, play crucial roles in the expansion of the disease. The mentioned risk factors can lead to the gradual or sudden emergence of new CL epidemics, and long-lasting endemic foci can also erupt into epidemics. This paper reviews the emerging epidemics published between 1998 and 2019 in Iran with particular emphasis on the operational aspects of control and related risk factors caused by anthroponotic CL (ACL) and zoonotic CL (ZCL). The competent surveillance system should be extended to all high-risk areas to facilitate controlling the emerging epidemics of ACL and ZCL in the affected areas.
Full-Text [PDF 730 kb]   (225 Downloads)    
Type of Study: Review article | Subject: Infectious diseases and public health
Received: 2019/07/2 | Accepted: 2020/01/11 | Published: 2020/03/9

References
1. Postigo JAR. Leishmaniasis in the world health organization eastern mediterranean region. Int J Antimicrob Agents. 2010; 36: S62-5. [DOI:10.1016/j.ijantimicag.2010.06.023]
2. World Health Organization. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. Geneva: World Health Organization; 2010.
3. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7 (5): e35671. [DOI:10.1371/journal.pone.0035671]
4. World Health Organization. Report on the interregional meeting on leishmaniasis among neighbouring endemic countries in the Eastern Mediterranean, African and European regions, Amman, Jordan 23-25 September 2018. World Health Organization, Regional Office for the Eastern Mediterranean; 2019. [DOI:10.26719/2019.25.1.66]
5. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004; 27 (5): 305-18. [DOI:10.1016/j.cimid.2004.03.004]
6. García AL, Parrado R, Rojas E, Delgado R, Dujardin J-C, Reithinger R. Leishmaniases in Bolivia: comprehensive review and current status. Am J Trop Med Hyg. 2009; 80 (5): 704-11. [DOI:10.4269/ajtmh.2009.80.704]
7. Bhutto AM, Soomro FR, Baloch JH, Matsumoto J, Uezato H, Hashiguchi Y, et al. Cutaneous leishmaniasis caused by Leishmania (L.) major infection in Sindh province, Pakistan. Acta Trop. 2009; 111 (3): 295-8. [DOI:10.1016/j.actatropica.2009.05.009]
8. Reithinger R, Mohsen M, Leslie T. Risk factors for anthroponotic cutaneous leishmaniasis at the household level in Kabul, Afghanistan. PLoS Negl Trop Dis. 2010; 4(3): e639. [DOI:10.1371/journal.pntd.0000639]
9. Ramaoui K, Guernaoui S, Boumezzough A. Entomological and epidemiological study of a new focus of cutaneous leishmaniasis in Morocco. Parasitol Res. 2008; 103 (4): 859-63. [DOI:10.1007/s00436-008-1068-3]
10. Faiman R, Abbasi I, Jaffe C, Motro Y, Nasereddin A, Schnur LF, et al. A newly emerged cutaneous leishmaniasis focus in northern Israel and two new reservoir hosts of Leishmania major. PLoS Negl Trop Dis. 2013; 7 (2): e2058. [DOI:10.1371/journal.pntd.0002058]
11. World Health Organization. Control of the leishmaniases: report of a meeting of the WHO Expert Commitee on the Control of Leishmaniases, Geneva, 22-26 March 2010. World Health Organization; 2010.
12. Amro A, Gashout A, Al-Dwibe H, Alam MZ, Annajar B, Hamarsheh O, et al. First molecular epidemiological study of cutaneous leishmaniasis in Libya. PLoS Negl Trop Dis. 2012; 6 (6): e1700. [DOI:10.1371/journal.pntd.0001700]
13. Aagaard‐Hansen J, Nombela N, Alvar J. Population movement: a key factor in the epidemiology of neglected tropical diseases. Trop Med Int Heal. 2010; 15 (11): 1281-8. [DOI:10.1111/j.1365-3156.2010.02629.x]
14. Ready PD. Leishmaniasis emergence in Europe. Eurosurveillance. 2010; 15 (10): 19505.
15. Shirzadi MR, Gouya MM. National Guidelines for cutaneous leishmaniasis surveillance in Iran. Minist Heal Med Educ (MOH) Zoonoses Control Dep Tehran Iran pp. 2012; 1-78.
16. Daszak P, Cunningham AA, Hyatt AD. Anthropogenic environmental change and the emergence of infectious diseases in wildlife. Acta Trop. 2001;78 (2): 103-16. [DOI:10.1016/S0001-706X(00)00179-0]
17. Askari A, Sharifi I, Aflatoonian MR, Babaei Z, Almani PGN, Mohammadi MA, et al. A newly emerged focus of zoonotic cutaneous leishmaniasis in South-Western Iran. Microb Pathog. 2018; 121: 363-8. [DOI:10.1016/j.micpath.2018.04.053]
18. Razavinasab SZ, Sharifi I, Aflatoonian MR, Babaei Z, Mohammadi MA, Salarkia E, et al. Expansion of urban cutaneous leishmaniasis into rural areas of southeastern Iran: Clinical, epidemiological and phylogenetic profiles explored using 7SL high resolution melting‐PCR analysis. Transbound Emerg Dis. 2019; 66 (1): 1602-10. [DOI:10.1111/tbed.13186]
19. Bamorovat M, Sharifi I, Aflatoonian MR, Sharifi H, Karamoozian A, Sharifi F, et al. Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran. PLoS One. 2018; 13 (2): e0192236. [DOI:10.1371/journal.pone.0192236]
20. Norouzinezhad F, Ghaffari F, Norouzinejad A, Kaveh F, Gouya MM. Cutaneous leishmaniasis in Iran: results from an epidemiological study in urban and rural provinces. Asian Pac J Trop Biomed. 2016; 6 (7): 614-9. [DOI:10.1016/j.apjtb.2016.05.005]
21. Ashford RW. The leishmaniases as emerging and reemerging zoonoses. Int J Parasitol. 2000; 30 (12-13): 1269-81. [DOI:10.1016/S0020-7519(00)00136-3]
22. Akhavan AA, Yaghoobi-Ershadi MR, Mehdipour D, Abdoli H, Farzinnia B, Mohebali M, et al. Epidemic outbreak of cutaneous leishmaniasis due to Leishmania major in Ghanavat rural district, Qom Province, Central Iran. Iran J Public Health. 2003; 35-41.
23. Rostami MN, Saghafipour A, Vesali E. A newly emerged cutaneous leishmaniasis focus in central Iran. Int J Infect Dis. 2013; 17 (12): e1198-206. [DOI:10.1016/j.ijid.2013.07.003]
24. Yaghoobi-Ershadi MR, Hanafi-Bojd AA, Akhavan AA, Zahrai-Ramazani AR, Mohebali M. Epidemiological study in a new focus of cutaneous leishmaniosis due to Leishmania major in Ardestan town, central Iran. Acta Trop. 2001; 79 (2): 115-21. [DOI:10.1016/S0001-706X(01)00085-7]
25. Aflatoonian MR, Sharifi I, Poursmaelian S, Hakimi-Parizi M, Ziaali N. The emergence of anthroponotic cutaneous leishmaniasis following the earthquake in southern villages of Bam district, southeastern Iran, 2010. J Arthropod Borne Dis. 2013; 7 (1): 8-14.
26. Khosravi A, Sharifi I, Dortaj E, Afshar AA, Mostafavi M. The present status of cutaneous leishmaniasis in a recently emerged focus in south-west of Kerman Province, Iran. Iran J Public Health. 2013; 42 (2): 182-7.
27. Sharifi I, Aflatoonian MR, Fekri AR. An epidemic of cutaneous leishmaniasis in Baft district in Kerman Province and its probable causative risk factors. Iran J Epidemiol. 2008; 4 (1): 53-8.
28. Akhavan AA, YaghoubiI Ershadi MR, Hasibi F, Jafari R, Abdoli H, Arandian MH, et al. Emergence of cutaneous leishmaniasis due to Leishmania major in a new focus of southern Iran. Iran J Arthropod Borne Dis. 2007; 1 (1): 1-8.
29. Sharifi I, Nakhaei N, Aflatoonian MR, Parizi MH, Fekri AR, Safizadeh H, et al. Cutaneous leishmaniasis in Bam: A comparative evaluation of pre-and post-earthquake years (1999-2008). Iran J Public Health. 2011; 40 (2): 49-56.
30. Aflatoonian MR, Sharifi I. The Epidemiology of Cutaneous Leishmaniasis in the City and Suburb of Bam in 2010: Active case-Finding, Treatment and Health Education of the School Children. 2011.
31. Sharifi I, Poursmaelian S, Aflatoonian MR, Ardakani RF, Mirzaei M, Fekri AR, et al. Emergence of a new focus of anthroponotic cutaneous leishmaniasis due to Leishmania tropica in rural communities of Bam district after the earthquake, Iran. Trop Med Int Heal. 2011; 16 (4): 510-3. [DOI:10.1111/j.1365-3156.2011.02729.x]
32. Aghaei Afshar A, Rassi Y, Sharifi I, Vatandoost H, Mollaie HR, Oshaghi MA, et al. First report on natural Leishmania infection of Phlebotomus sergenti due Leishmania tropica by high resolution melting curve method in Southeastern Iran. Asian Pac J Trop Med. 2014; 93-6. [DOI:10.1016/S1995-7645(14)60002-X]
33. Aghaei Afshar A, Rassi Y, Sharifi I, Abai MR, Oshaghi MA, Yaghoobi-Ershadi MR, et al. Susceptibility status of Phlebotomus papatasi and P. sergenti (Diptera: Psychodidae) to DDT and deltamethrin in a focus of cutaneous leishmaniasis after earthquake strike in Bam, Iran. Iran J Arthropod Borne Dis. 2011; 5 (2): 32-41.
34. Aghasi M, Sharifi I. Survey of the fauna and monthly activity of the sandfly as the vectors of the cutaneous leishmaniasis in the City of Bam. J Kerman Univ Med Sci. 2003; 10 (2): 85-91.
35. Yaghoobi-Ershadi MR, Hanafi-Bojd AA, Javadian E, Jafari R, Zahraei-Ramazani AR, Mohebali M. A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Med J. 2002; 23 (3): 291-4.
36. Stockdale L, Newton R. A review of preventative methods against human leishmaniasis infection. PLoS Negl Trop Dis. 2013; 7 (6): e2278. [DOI:10.1371/journal.pntd.0002278]
37. Yaghoobi-Ershadi MR, Akhavan AA. Entomological survey of sandflies (Diptera: Psychodidae) in a new focus of zoonotic cutaneous leishmaniosis in Iran. Acta Trop. 1999; 73 (3): 321-6. [DOI:10.1016/S0001-706X(99)00038-8]
38. Rassi Y, Saghafipour A, Abai MR, Oshaghi MA, Rafizadeh S, Mehdi M, et al. Phlebotomus papatasi and Meriones libycus as the vector and reservoir host of cutaneous leishmaniasis in Qomrood District, Qom Province, central Iran. Asian Pac J Trop Med. 2011; 4 (2): 97-100. [DOI:10.1016/S1995-7645(11)60045-X]
39. Parvizi P, Ready PD. Nested PCRs and sequencing of nuclear ITS‐rDNA fragments detect three Leishmania species of gerbils in sandflies from Iranian foci of zoonotic cutaneous leishmaniasis. Trop Med Int Heal. 2008; 13 (9): 1159-71. [DOI:10.1111/j.1365-3156.2008.02121.x]
40. Rassi Y, Abai MR, Javadian E, Rafizadeh S, Imamian H, Mohebali M, et al. Entomologie medicale. Bull Soc Pathol Exot. 2008; 101 (5): 425-8.
41. Azizi K, Rassi Y, Moemenbellah-Fard MD. PCR-based detection of Leishmania major kDNA within naturally infected Phlebotomus papatasi in southern Iran. Trans R Soc Trop Med Hyg. 2010; 104 (6): 440-2. [DOI:10.1016/j.trstmh.2010.01.008]
42. Mohebali M, Javadian E, Yaghoobi Ershadi MR, Akhavan AA, Hajjaran H, Abaei MR. Characterization of Leishmania infection in rodents from endemic areas of the Islamic Republic of Iran. EMHJ-Eastern Mediterr Heal J. 2004; 10 (4-5): 591-9.
43. Oshaghi MA, Yaghobi-Ershadi MR, Abbassi M, Parvizi P, Akhavan AA, Foroshani AR, et al. Detection of Leishmania major in naturally infected sand flies using semi nested-PCR. Iran J Public Health. 2008; 59-64.
44. Mirzaei M, Sharifi I, Poursmaelian S. A new focus of anthroponotic cutaneous leishmaniasis and identification of parasite species by nested PCR in Jiroft, Iran. Comp Clin Path. 2012; 21 (5): 1071-5. [DOI:10.1007/s00580-011-1231-6]
45. Fazaeli A, Fouladi B, Sharifi I. Emergence of cutaneous leishmaniasis in a border area at south-east of Iran: an epidemiological survey. J Vector Borne Dis. 2009; 46 (1): 36-42.
46. Razmjou S, Hejazy H, Motazedian MH, Baghaei M, Emamy M, Kalantary M. A new focus of zoonotic cutaneous leishmaniasis in Shiraz, Iran. Trans R Soc Trop Med Hyg. 2009; 103 (7): 727-30. [DOI:10.1016/j.trstmh.2008.12.013]
47. Sharifi I, Fekri AR, Aflatoonian MR, Khamesipour A, Mahboudi F, Dowlati Y, et al. Leishmaniasis recidivans among school children in Bam, South‐east Iran, 1994-2006. Int J Dermatol. 2010; 49 (5): 557-61. [DOI:10.1111/j.1365-4632.2010.04419.x]
48. Hejazi H, Mirmohammad SH, Dabirzadeh M, Nilforoushzadeh MA, Baghaei M. Atypical clinical forms of zoonotic cutaneous Leishmaniasis due ro leishmania major in Isfahan, Iran. 2007; 25 (8): 43-9.
49. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005; 366 (9496): 1561-77. [DOI:10.1016/S0140-6736(05)67629-5]
50. Ramezany M, Sharifi I, Babaei Z, Ghasemi Nejad Almani P, Heshmatkhah A, Keyhani A, et al. Geographical distribution and molecular characterization for cutaneous leishmaniasis species by sequencing and phylogenetic analyses of kDNA and ITS1 loci markers in south-eastern Iran. Pathog Glob Health. 2018; 1-10. [DOI:10.1080/20477724.2018.1447836]
51. Bamorovat M, Sharifi I, Mohammadi MA, Eybpoosh S, Nasibi S, Aflatoonian MR, et al. Leishmania tropica isolates from non-healed and healed patients in Iran: A molecular typing and phylogenetic analysis. Microb Pathog. 2018; [DOI:10.1016/j.micpath.2018.01.021]
52. Croft SL, Olliaro P. Leishmaniasis chemotherapy-challenges and opportunities. Clin Microbiol Infect. 2011; 17 (10): 1478-83. [DOI:10.1111/j.1469-0691.2011.03630.x]
53. Khosravi A, Sharifi I, FekriI A, Kermanizadeh A, Bamorovat M, Mostafavi M, et al. Clinical Features of Anthroponotic Cutaneous Leishmaniasis in a Major Focus, Southeastern Iran, 1994-2014. Iran J Parasitol. 2017; 12 (4): 544.
54. Oliaee RT, Sharifi I, Afgar A, Kareshk AT, Asadi A, Heshmatkhah A, et al. Unresponsiveness to meglumine antimoniate in anthroponotic cutaneous leishmaniasis field isolates: analysis of resistance biomarkers by gene expression profiling. Trop Med Int Heal. 2018; [DOI:10.1111/tmi.13062]
55. Aflatoonian MR, Sharifi I, Aflatoonian B, Bamorovat M, Heshmatkhah A, Babaei Z, et al. Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran. PLoS Negl Trop Dis. 2019; 13 (6): e0007423. [DOI:10.1371/journal.pntd.0007423]
56. Yaghoobi-Ershadi MR, Jafari R, Hanafi-Bojd AA. A new epidemic focus of zoonotic cutaneous leishmaniasis in central Iran. Ann Saudi Med. 2004; 24 (2): 98-101. [DOI:10.5144/0256-4947.2004.98]
57. Yaghoobi Ershadi MR, Akhavan AA, Zahraei Ramazani A V, Abai MR, Ebrahimi B, Vafaei Nezhad R, et al. Epidemiological study in a new focus of cutaneous leishmaniasis in the Islamic Republic of Iran. East Mediterr Heal J. 2003; 9 (4): 816-26.
58. Pouresmaeelian S, Sharifi I, Aflatoonian MR. A new focus of anthroponotic cutaneous leishmaniasis in Dehbakry region of Bam district, southeastern Iran 2008. J Kerman Univ Med Sci. 2015; 17 (1): 15-24.
59. Fakoorziba MR, Baseri A, Eghbal F, Rezaee S, Azizi K, Moemenbellah-Fard MD. Post-earthquake outbreak of cutaneous leishmaniasis in a rural region of southern Iran. Ann Trop Med Parasitol. 2011; 105 (3): 217-24. [DOI:10.1179/136485911X12899838683449]
60. Yaghoobi-Ershadi MR, Hakimiparizi M, Zahraei-Ramazani AR, Abdoli H, Akhavan AA, Aghasi M, et al. Sand fly surveillance within an emerging epidemic focus of cutaneous leishmaniasis in southeastern Iran. Iran J Arthropod Borne Dis. 2010; 4 (1): 17-23.
61. Ghaffari D, Parizi MH, Ershadi MRY, Sharifi I, Akhavan AA. A survey of reservoir hosts in two foci of cutaneous leishmaniasis in Kerman province, southeast of Iran. J Parasit Dis. 2014; 38 (3): 245-9. [DOI:10.1007/s12639-013-0275-8]
62. WHO. Control of the leishmaniases: report of a meeting of the WHO expert committee on the control of leishmaniases. In: Control of the leishmaniases: report of a meeting of the WHO expert committee on the control of leishmaniases. World Health Organization; 2010.
63. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res. 2007; 101 (5): 1319-22. [DOI:10.1007/s00436-007-0638-0]
64. Pour R, Sharifi I, Kazemi B, Zarean M. Identification of nonresponsive isolates to Glucantime in patients with cutaneous Leishmanaisis in Bam. J Kerman Univ Med Sci. 2015; 2 (1): 123-33.
65. Esfandiarpour I, Dabiri SH. Treatment of cutaneous leishmaniasis recidivans with a combination of allopurinol and meglumine antimoniate: a clinical and histologic study. Int J Dermatol. 2007; 46 (8): 848-52. [DOI:10.1111/j.1365-4632.2007.03086.x]
66. Nadim A, Motahar M, Houshmand B, Keyghobadi K, Aflatoonian MR. Evaluation of pyrethroid impregnated bednets for control of anthroponotic cutaneous leishmaniasis in Bam (‎Islamic Republic of Iran)‎. In World Health Organization; 1995; 21.
67. Nadim A, Aflatoonian MR. Anthroponotic cutaneous leishmaniasis in the city of Bam, southeast Iran. Iran J Public Health. 1995; 24 (1-2): 15-24.
68. Noazin S, Shirzadi MR, Kermanizadeh A, Yaghoobi-Ershadi M-R, Sharifi I. Effect of large-scale installation of deltamethrin-impregnated screens and curtains in Bam, a major focus of anthroponotic cutaneous leishmaniasis in Iran. Trans R Soc Trop Med Hyg. 2013; 107 (7): 444-50. [DOI:10.1093/trstmh/trt036]
69. Aghaei Afshar A, Vatandoost H, Sharifi I, Rassi Y, Abai MR, Oshaghi MA, et al. First determination of impact and outcome indicators following indoor residual spraying (IRS) with deltamethrin in a new focus of anthroponotic cutaneous leishmaniasis (ACL) in Iran. Asian Pacific J Trop Dis. 2013; 3 (1): 5-9. [DOI:10.1016/S2222-1808(13)60002-X]
70. Saeidi Z, Vatandoost H, Akhavan AA, Yaghoobi‐Ershadi MR, Rassi Y, Sheikh Z, et al. Baseline susceptibility of a wild strain of Phlebotomus papatasi (Diptera: Psychodidae) to DDT and pyrethroids in an endemic focus of zoonotic cutaneous leishmaniasis in Iran. Pest Manag Sci. 2012; 68 (5): 669-75. [DOI:10.1002/ps.2278]
71. Abolghasemi H, Radfar MH, Khatami M, Nia MS, Amid A, Briggs SM. International medical response to a natural disaster: lessons learned from the Bam earthquake experience. Prehosp Disaster Med. 2006; 21 (3): 141-7. [DOI:10.1017/S1049023X00003599]
72. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001; 95 (3): 239-43. [DOI:10.1016/S0035-9203(01)90223-8]
73. Oshaghi MA, Rasolian M, Shirzadi MR, Mohtarami F, Doosti S. First report on isolation of Leishmania tropica from sandflies of a classical urban cutaneous leishmaniasis focus in southern Iran. Exp Parasitol. 2010; 126 (4): 445-50. [DOI:10.1016/j.exppara.2010.05.020]
74. Yaghoobi-Ershadi MR, Akhavan AA, Mohebali M. Monthly variation of Leishmania major MON-26 infection rates in Phlebotomus papatasi (Diptra: Psychodidae) from rodent burrows in Badrood area of Iran. Med J Islam Repub Iran. 2001; 15 (3): 175-8.
75. Abai MR, Oshaghi MA, Tajedin L, Rassi Y, Akhavan AA. Geographical distribution and ecological features of the great gerbil subspecies in the main zoonotic cutaneous leishmaniasis foci in Iran. Asian Pac J Trop Med. 2010; 3 (10): 800-3. [DOI:10.1016/S1995-7645(10)60192-7]
76. Ershadi M-RY, Zahraei-Ramazani A-R, Akhavan A-A, Jalali-Zand A-R, Abdoli H, Nadim A. Rodent control operations against zoonotic cutaneous leishmaniasis in rural Iran. Ann Saudi Med. 2005; 25 (4): 309-12. [DOI:10.5144/0256-4947.2005.309]
77. Yaghoobi-Ershadi MR, Akhavan AA, Zahraei-Ramazani AR, Javadian E, Motavalli-Emami M. Field trial for the control of zoonotic cutaneous leishmaniosis in Badrood, Iran. Ann Saudi Med. 2000; 20 (5-6): 386-9. [DOI:10.5144/0256-4947.2000.386]
78. Yaghoobi-Ershadi MR, Akhavan AA, Mohebali M. Meriones Iibycus and Rhombomys opimus (Rodentia: Gerbillidae) are the main reservoir hosts in a new focus of zoonotic cutaneous leishmaniasis in Iran. Trans R Soc Trop Med Hyg. 1996; 90 (5): 503-4. [DOI:10.1016/S0035-9203(96)90295-3]
79. Bamorovat M, Sharifi I, Mohammadi MA, Harandi MF, Mohebali M, Afshar RM, et al. Canine visceral leishmaniasis in Kerman, southeast of Iran: a seroepidemiological, histopathological and molecular study. Iran J Parasitol. 2014; 9 (3): 342.
80. Bamorovat M, Sharifi I, Dabiri S, Mohammadi MA, Harandi MF, Mohebali M, et al. Leishmania tropica in stray dogs in southeast Iran. Iran J Public Health. 2015; 44 (10): 1359-66.
81. Abbaszadeh MJA, Sharifi I, Bamorovat M, Mohebali M, Bahreini MS, Naderi A. Canine Visceral Leishmaniasis; A Seroepidemiological Survey in Jiroft District, Southern Kerman Province, Southeastern Iran in 2015. Iran J Parasitol. 2018; 13 (1): 67-71.
82. Moshfe A, Mohebali M, Edrissian G, Zarei Z, Akhoundi B, Kazemi B, et al. Canine visceral leishmaniasis: asymptomatic infected dogs as a source of L. infantum infection. Acta Trop. 2009; 112 (2): 101-5. [DOI:10.1016/j.actatropica.2009.07.004]
83. Mohebali M, Hajjaran H, Hamzavi Y, Mobedi I, Arshi S, Zarei Z, et al. Epidemiological aspects of canine visceral leishmaniosis in the Islamic Republic of Iran. Vet Parasitol. 2005; 129 (3-4): 243-51. [DOI:10.1016/j.vetpar.2005.01.010]
84. Sharifi I, Fekri AR, Aflatonian M-R, Khamesipour A, Nadim A, Mousavi M-RA, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998; 351 (9115): 1540-3. [DOI:10.1016/S0140-6736(98)09552-X]
85. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine. 2008; 26 (52): 6759-67. [DOI:10.1016/j.vaccine.2008.09.085]
86. Sharifi F, Sharifi I, Zarean M, Parizi MH, Aflatoonian MR, Harandi MF, et al. Spatial distribution and molecular identification of Leishmania species from endemic foci of south-eastern Iran. Iran J Parasitol. 2012; 7 (1): 45-52.
87. Aflatoonian MR, Sharifi I, Parizi MH, Fekri AR, Aflatoonian B, Sharifi M, et al. A prospective cohort study of cutaneous leishmaniasis risk and opium addiction in south eastern Iran. PLoS One. 2014; 9 (2): e89043. [DOI:10.1371/journal.pone.0089043]
88. Tangie LN, Desmond A, Aminde LN, Ako AM, Halle PM. Cutaneous leishmaniasis in a severely immunocompromised HIV patient in Kumbo, Northwest region of Cameroon: case report. BMC Res Notes. 2017; 10 (1): 425. [DOI:10.1186/s13104-017-2751-1]
89. Bamorovat M, Sharifi I, Fekri A, Keyhani A, Aflatoonian MR, Heshmatkhah A, et al. A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models. Microb Pathog. 2019; 128: 162-70. [DOI:10.1016/j.micpath.2018.12.040]
90. Gupta S. Return of kala-azar. J Indian Med assossiation. 1991; 65: 89-90.

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.